Process Validation Guidances FDA and Global
-
Upload
institute-of-validation-technology -
Category
Documents
-
view
7.166 -
download
4
Transcript of Process Validation Guidances FDA and Global
![Page 1: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/1.jpg)
1
PROCESS VALIDATION GUIDANCES FDA AND GLOBAL
Paul L. Pluta, PhD
Journal of Validation Technology Journal of GXP Compliance
University of Illinois at Chicago (UIC) College of Pharmacy Chicago, IL, USA
![Page 2: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/2.jpg)
OUTLINE Process Validation Lifecycle Approach Overview • History and development • Is the lifecycle approach really new? • FDA commentary Lifecycle Approach Stages • #1 -- Process Understanding (Process Design) • #2 -- Process Demonstration (Process Qualification) • #3 -- Maintaining Validation (Continued Process Verification) Fundamental Concepts • The “process of process validation” • Enhanced execution • Comparison to traditional approach Regulatory Guidances • Health Canada • FDA • EMA Applications of PV Guidance • Processes: Manufacturing, cleaning, packaging, analytical, others • Equipment, facilities, utilities, others • Quality Systems Implementation • Implementation is difficult
2
![Page 3: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/3.jpg)
OBJECTIVES
• What is the lifecycle approach? • Is the lifecycle approach new? • How is it different? • What are fundamental principles? • US only or global? • Is industry accepting this approach? • Audit questions:
What is your approach to validation? What is your approach to quality systems?
3
![Page 4: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/4.jpg)
VALIDATION MANAGER COMMENTARY
Organizations implementing lifecycle approach -- Reasons • US FDA guidance • Health Canada guidance • EMA draft guidance • Global communication • ICH Q8, Q11 • Logical approach – development, performance, and maintenance • Application to other processes, equipment, facilities, etc.
Organizations not implementing lifecycle approach -- Reasons • “Its only a guidance.” • “Let’s see what happens.” • “It’s only for USA.” • “We will consider it if we get observations.” • Too costly, no headcount
4
![Page 5: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/5.jpg)
PROCESS VALIDATION LIFECYCLE APPROACH OVERVIEW
• History and Development • Fundamental Concepts • Consistency with Medical Devices • Is the lifecycle approach really new?
5
![Page 6: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/6.jpg)
HISTORY AND DEVELOPMENT – LIFECYCLE APPROACH
2004 – Health Canada guidance 2005 – FDA initial presentations 2007 – ICH Q10 2008 – FDA draft guidance 2009 – ICH Q8(R2) 2009 – Health Canada revision 2011 – FDA guidance issued 2012 – EMA draft guidance
6
![Page 7: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/7.jpg)
PROCESS VALIDATION LIFECYCLE APPROACH A NEW PARADIGM FOR PHARMA –
IS IT REALLY NEW?
Health Canada introduces lifecycle phases in 2004. FDA lifecycle approach (stages) to process validation
incorporated concepts of ICH Q8, Q9, Q10, QbD, and PAT – presentations starting 2005.
Many concepts previously mentioned in documents issued before 2000.
See slides 8-41.
7
![Page 8: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/8.jpg)
HEALTH CANADA -- VALIDATION GUIDELINES FOR PHARMACEUTICAL DOSAGE FORMS (GUI-0029)
5.0 Phases of Validation Phase 1: Pre-Validation Phase Phase 2: Process Validation Phase (Process Qualification Phase Phase 3: Validation Maintenance Phase 6.0 Interpretation Validation protocol Validation Master Plan Installation and Operational Qualification • IQ • OQ • Re-Qualification • Process validation • Prospective validation • Matrix or family approaches to prospective process validation • Concurrent validation • Retrospective validation • Process Re-Validation • Change control
8
![Page 9: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/9.jpg)
ICH Q8 (R2) PHARMACEUTICAL DEVELOPMENT
Objectives • Harmonized regulatory submissions (CTD) • Principles of Quality by Design (QbD) • Consistent with Q9 Risk Management
Problems addressed • Inconsistency between all regions • Inconsistent content • Inclusion of development information
9
![Page 10: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/10.jpg)
ICH Q8 PHARMACEUTICAL DEVELOPMENT Drug product development considerations • Components: API and excipients • Formulation development • Overages • Physicochemical and biological properties • Manufacturing process development • Container-closure systems • Microbiological attributes • Compatibility
10
![Page 11: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/11.jpg)
ICH Q8 PHARMACEUTICAL DEVELOPMENT Key points “Information and knowledge gained from development
studies and manufacturing experience provides scientific understanding to support the establishment of the design space, specifications, and manufacturing controls.”
“Pharmaceutical development section should describe the knowledge…”
“At a minimum, those aspects of drug substances, excipients, … that are critical to product quality should be determined and control strategies justified.”
“…demonstrate a higher degree of understanding of material attributes, manufacturing processes …”
11
![Page 12: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/12.jpg)
ICH Q8 PHARMACEUTICAL DEVELOPMENT
Key points • Examination • Understanding • Evaluation • Identification • Rationale and justification • Others
Discussion in submission
12
![Page 13: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/13.jpg)
ICH Q8 PHARMACEUTICAL DEVELOPMENT
Implications for Process Validation • Process understanding • Process development studies are basis for
process validation • Continuous process verification is
alternate to process validation
13
![Page 14: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/14.jpg)
ICH Q9 QUALITY RISK MANAGEMENT
Objectives • Effective application of risk management • Consistent science-based decisions • Incorporate risk management into practice
Problems addressed • Inconsistent risk-management application • Common understanding
14
![Page 15: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/15.jpg)
ICH Q9 QUALITY RISK MANAGEMENT
• Principles of quality risk management • General process: Initiation, assessment, control,
communication, review • Methodology • Integration into industry and regulatory
operations • Methods and tools • Potential specific applications
15
![Page 16: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/16.jpg)
ICH Q9 QUALITY RISK MANAGEMENT Initiate risk management process Risk assessment • Risk identification • Risk analysis • Risk evaluation Risk control • Risk reduction • Risk acceptance
Output Risk review 16
![Page 17: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/17.jpg)
ICH Q9 QUALITY RISK MANAGEMENT
Risk Management Methods and Tools • Basic methods: Flow charts, process maps,
cause and effect (fishbone) diagrams • FMEA / FMECA • FTA • HAACP • HAZOP • PHA • Risk ranking and filtering
17
![Page 18: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/18.jpg)
ICH Q9 QUALITY RISK MANAGEMENT Applications • Integrated quality management: Documentation,
training, defects, auditing, periodic review, change control, improvements
• Regulatory operations • Development: Process knowledge, PAT development • Facilities, equipment, utilities: Design, qualification,
cleaning, calibration, PM • Materials management: Material variation • Production: Validation, in-process testing • Laboratory control and stability • Packaging and labeling 18
![Page 19: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/19.jpg)
ICH Q9 QUALITY RISK MANAGEMENT
Key points • Methods of evaluation • Potential applications – every function,
every activity, entire product lifecycle
19
![Page 20: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/20.jpg)
ICH Q9 QUALITY RISK MANAGEMENT
Implications for Process Validation • Development: Process knowledge • Materials: Variation, change control • Equipment: Qualification, cleaning,
calibration, PM, change control • Production: Validation, sampling, testing,
change control • Maintenance / monitoring: Testing 20
![Page 21: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/21.jpg)
ICH Q10 PHARMACEUTICAL QUALITY SYSTEMS
Objectives • Global harmonization of quality systems • Consistency with ICH Q8 and Q9 • Application throughout product lifecycle
Problems addressed • Inconsistent application • Inconsistent definitions of common terminology
21
![Page 22: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/22.jpg)
ICH Q10 PHARMACEUTICAL QUALITY SYSTEMS
• Overview and definitions • Management responsibility: Commitment, policy,
planning, resources, communication, review, outsourcing • Continual improvement of performance and quality:
Lifecycle stages and elements • Continual improvement of quality system: Management,
monitoring, outcomes
22
![Page 23: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/23.jpg)
ICH Q10 PHARMACEUTICAL QUALITY SYSTEMS
Key points • Quality system application throughout product lifecycle
– Pharmaceutical development – Technology transfer – Manufacturing – Product discontinuation
• Product realization, maintain control, improvements • Enable by knowledge and risk management • Management responsibility: Commitment, policy,
planning, resources, communication, review, outsourcing oversight
23
![Page 24: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/24.jpg)
ICH Q10 PHARMACEUTICAL QUALITY SYSTEMS
Key points Continual improvement • Product performance / quality monitoring system
– Control strategy, identify variation, problem feedback, enhance process understanding
• CAPA system – Enhance process understanding
• Change management system – Risk management, evaluation, technical justification
• Management review – Audits, inspections, changes, CAPA, etc.
24
![Page 25: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/25.jpg)
ICH Q10 PHARMACEUTICAL QUALITY SYSTEMS
Implications for Process Validation • Product performance and monitoring • CAPA system enhances process understanding
• Change management system • Process improvements
25
![Page 26: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/26.jpg)
ICH Q11 DEVELOMENT AND MANUFACTURE OF
DRUG SUBSTANCES
• Consistent with ICH Q8, Q9, and Q10 • Lifecycle approach • CQA, CPP • Design space • Control of variables • Process validation • Risk management
26
![Page 27: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/27.jpg)
QUALITY BY DESIGN (QbD)
1. Quality target product profile (QTTP) 2. Critical quality attributes (CQA), critical material
attributes (CMA) 3. Critical process parameters (CPP) 4. Design space 5. Scale-up and technology transfer 6. Identify input variables 7. Input variable control strategy 8. Continuous improvement
Other considerations: PAT, risk analysis
27
![Page 28: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/28.jpg)
SUPPORTING DOCUMENTS PROCESS VALIDATION – 1987 GUIDANCE
Assurance of product quality: • Quality parts and materials • Adequate product and process design • Control of the process • In-Process and end-product testing.
Basic principles: • Quality, safety, and effectiveness designed and built into the product • Quality cannot be inspected or tested in the product • Each process step must be controlled to maximize meeting quality and design specifications. R&D phase: Product definition and characteristics Equipment and process Equipment: Installation Qualification Process: Performance Qualification Product (devices only): Performance Qualification Revalidation. Change control Documentation. Proper maintenance of documentation Reference: FDA Guideline on General Principles of Process Validation. May, 1987
28
![Page 29: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/29.jpg)
29
SUPPORTING DOCUMENTS VALIDATION – PHARMACEUTICAL DOSAGE FORMS
FDA INSPECTION GUIDELINES Three phases of the validation process: • Product development • Design of the validation protocol • Demonstration runs (validation) – full scale
Process validation: • Documented evidence • Consistency • Predetermined specifications
Documented evidence includes experiments, data, and results
Product Development Reports
Control of the physical characteristics of the excipients
Particle size testing of multi-source excipients
Critical process parameters
Development data serves as the foundation for the manufacturing procedures
Variables are identified in the development phase
Raw materials may vary lot-to-lot
References: FDA Guides to Inspections. Oral Solid Dosage Forms (January 1994), Topical Drug Products (July 1994), Oral Solutions and Suspensions (August 1994)
![Page 30: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/30.jpg)
30
SUPPORTING DOCUMENTS VALIDATION – MEDICAL DEVICES
Planning the Process Validation Study Installation and Operational Qualification Process Performance Qualification • Eliminate controllable causes of variation Product Performance Qualification • Evaluate routine production process monitoring data for trends
Process operating in a state of control is determined by analyzing
day-to-day process control data and finished device test data for conformance with specifications and for variability.
Reference: FDA Medical Device Quality Systems Manual. January 07, 1997
![Page 31: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/31.jpg)
31
SUPPORTING DOCUMENTS PROCESS VALIDATION – API
Critical parameters / attributes identified during development
Qualification of equipment and systems: DQ, IQ, OQ, PQ. Process Validation Program Critical process parameters controlled and monitored Non-critical parameters not included in validation Periodic review of validated systems Reference: ICH Q7. Good Manufacturing Practice Guide for Active Pharmaceutical
Ingredients. November, 2000.
![Page 32: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/32.jpg)
32
SUPPORTING DOCUMENTS PROCESS VALIDATION – PRODUCTS / API
A validated manufacturing process has a high level of scientific assurance that it will reliably product acceptable product.
Proof of validation is obtained through rational experimental design and the ongoing evaluation of data, preferably beginning from the process development phase continuing through the commercial production phase.
Reference: FDA Section 490.199. CPG 7132c.08. Process Validation
Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval. 2004 revision.
![Page 33: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/33.jpg)
33
SUPPORTING DOCUMENTS PROCESS VALIDATION – PRODUCTS / API
Before commercial distribution: • Product and process development • Scale-up studies • Equipment and system qualification • Conformance batches
Identify and control all critical sources of variability Advance manufacturing control technology may
eliminate validation lots. Reference: FDA Section 490.199. CPG 7132c.08. Process Validation
Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval. 2004 revision.
![Page 34: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/34.jpg)
34
SUPPORTING DOCUMENTS VALIDATION -- PHARMACEUTICAL CGMPS
Cross-Agency workgroup CDER, CBER, ORA, and CVM.
“The CPG clearly signals that a focus on three full-scale production batches would fail to recognize the complete story on validation.”
Reference: FDA. Pharmaceutical CGMPs for the 21st
Century – A Risk-Based Approach. Final Report, September 2004.
![Page 35: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/35.jpg)
35
SUPPORTING DOCUMENTS PROCESS VALIDATION – MEDICAL DEVICES
Process evaluation – Validation or verification Protocol development
– Processes well thought out – What could go wrong
Installation Qualification Operational Qualification
– “Worst case” testing – DOE and screening studies
Performance Qualification – Process repeatability
Attributes for continuous post-validation monitoring and maintenance Eliminate controllable causes of variation. Maintaining a state of validation – Monitor and control Change control Statistical Methods Risk Analysis Methods
Reference: Global Harmonization Task Force (GHTF) Study Group 3. Quality Management Systems – Process Validation Guidance. January 2004.
![Page 36: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/36.jpg)
36
SUPPORTING DOCUMENTS VALIDATION – INTERNATIONAL
PIC/S PHARMACEUTICAL INSPECTION CONVENTION
A series of experiments should be devised to determine the criticality of process parameters / factors
Test processes with starting materials on the extremes of specification
Monitoring and in-process controls Reference: PIC/S Recommendations on Validation. July 2004.
![Page 37: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/37.jpg)
37
SUPPORTING DOCUMENTS FDA -- QUALITY BY DESIGN (QbD)
• Product is designed to meet patient requirements • Process is designed to consistently meet product
critical quality attributes • Impact of starting materials and process parameters on
product quality is understood • Critical sources of process variability are identified and
controlled • Process is continually monitored and updated to
assure consistent quality over time Reference: FDA. Chi-wan Chen, ISPE, Japan, June, 2006
![Page 38: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/38.jpg)
38
SUPPORTING DOCUMENTS PROCESS ROBUSTNESS (PQRI)
Robust Process: Able to tolerate expected variability of raw materials, operating conditions, process equipment, environmental conditions, and human factors
• Development • Maintenance
Process understanding is key to developing a
robust process. Reference: Product Quality Research Institute (PQRI). Pharmaceutical
Engineering, November-December, 2006
![Page 39: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/39.jpg)
39
SUPPORTING DOCUMENTS ASTM WK 9935 Standard Guide
Continuous Quality Verification (CQV) A Science and Risk-Based Alternative Approach to
Traditional Process Validation of Biopharmaceutical and Pharmaceutical Manufacturing Processes
CONTINUOUS QUALITY VERIFICATION Process design / Risk assessment / Process
understanding • Development phase • Scale-up phase • Commercialization phase
Process capability evaluation Continuous process improvement
![Page 40: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/40.jpg)
40
SUPPORTING DOCUMENTS PROCESS ANALYTICAL TECHNOLOGY (PAT)
Processes verified by PAT are not validated
All associated PAT equipment and analytical methods are validated
Reference: FDA. PAT -- A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. September 2004
![Page 41: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/41.jpg)
41
SUPPORTING DOCUMENTS PROCESS ANALYTICAL TECHNOLOGY (PAT)
Process Understanding • All critical sources of variability are identified and explained. • Variability is managed by the process • Product quality attributes can be accurately and reliably
predicted over the design space • Materials used • Process parameters • Manufacturing • Environmental • Other conditions
Reference: FDA. PAT -- A Framework for Innovative Pharmaceutical
Development, Manufacturing, and Quality Assurance. September 2004
![Page 42: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/42.jpg)
LIFECYCLE APPROACH OVERVIEW
• The “process of process validation” • Process understanding, demonstration, and
maintaining the validated state throughout entire commercial life of product.
• Comparison to previous approach
42
![Page 43: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/43.jpg)
PROCESS VALIDATION HISTORY 1978 FDA CGMP includes Validation 1987
Development -- VALIDATION -- Control
2004-2011 Lifecycle approach Continuum of understanding – validation – maintenance
UNDERSTANDING -- VALIDATION -- MAINTENANCE
43
![Page 44: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/44.jpg)
FDA 2011 PV GUIDANCE – PROCESS VALIDATION REVISITED Paula Katz (FDA) and Cliff Campbell
JGXP Compliance, Vol .16, #4, Fall, 2012
Among other motivating factors, the Agency sought to emphasize process design and maintenance of process control during commercialization. By aligning process validation activities with a lifecycle approach, the 2011 Guidance communicates that process validation is an ongoing program rather than a discrete and isolated activity. Under the 2011 Guidance, process validation is presented as a series of activities that manufacturers carry out over the lifecycle of the product and process. This view of process validation underscores the importance of detecting, understanding, and controlling sources of variability over time in order to consistently produce safe, effective drugs that meet all quality attributes. In turn, the emphasis on understanding and controlling process variability leads to a clarification that the Agency expects manufacturers to employ objective measures and appropriate statistical tools and analysis.
44
![Page 45: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/45.jpg)
PROCESS VALIDATION GUIDANCES
• Health Canada • FDA • EMA
45
![Page 46: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/46.jpg)
HEALTH CANADA -- VALIDATION GUIDELINES FOR PHARMACEUTICAL DOSAGE FORMS, 2009
Phase 1. Pre-validation phase or qualification phase. Product R&D, pilor studies, scale-up, stability studies, equipment qualification, IQ, OQ, master production documents, others.
Phase 2. Process validation phase or process qualification phase. Verify that all limits of critical process parameters are valid and satisfactory product produced under worst-case conditions.
Phase 3. Validation maintenance phase. Frequent reviews of process-related documents to assure no changes, deviations, or failures, and that SOPs have been followed, including change control No changes that should have results in revalidation.
46
![Page 47: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/47.jpg)
FDA PROCESS VALIDATION GUIDANCE (2011) Definition: Collection and evaluation of data, from the
process design stage throughout commercial production, which establishes scientific evidence that a process is capable of consistently delivering quality products. Process validation involves a series of activities over the lifecycle of the product and process.
Three stages of activities: • Stage 1 – Process Design – Development and scale-up activities • Stage 2 – Process Qualification – Demonstrate reproducible
manufacturing through conformance lots • Stage 3 – Continued Process Verification – Routine manufacturing
and monitoring of performance.
STAGE 1 AND STAGE 3 EMPHASIS – NEW PARADIGM
47
![Page 48: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/48.jpg)
FDA PROCESS VALIDATION GUIDANCE
“Before …commercial distribution to consumers, a manufacturer should have gained a high degree of assurance in the performance of the manufacturing process…consistently produce …”
Manufacturers should: • Understand the sources of variation • Detect the presence and degree of variation • Understand the impact of variation on the process and product
attributes • Control the variation in a manner commensurate with risk to process
and product.”
“…to justify commercial distribution of the product.”
“… use ongoing programs to collect and analyze product and process data … state if control of the process.”
48
![Page 49: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/49.jpg)
FDA PROCESS VALIDATION GUIDANCE
Good project management and good archiving to capture scientific knowledge.
Enhance accessibility of information later in lifecycle. Integrated team approach: Process engineering, industrial
pharmacy, analytical chemistry, microbiology, statistics, manufacturing, and quality assurance.
Scientific studies throughout the product lifecycle planned, documented, and approved.
Greater control over higher-risk attributes. Reevaluate risks throughout product/process lifecycle. Homogeneity with batch and consistency between batches
are goals of process validation. 49
![Page 50: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/50.jpg)
50
STAGE 1, PROCESS DESIGN (PROCESS UNDERSTANDING)
1. Building and capturing process knowledge and understanding.
2. Establishing a strategy for process control.
Define commercial-scale process Define unit operations and process parameters Identify and understand sources of variability Identify critical process parameters Studies to understand effects of scale Establish mechanisms to control variability • Process Analytical Technology Designed experiments Lab scale and pilot scale experiments
![Page 51: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/51.jpg)
PROCESS DESIGN (PROCESS UNDERSTANDING)
Objective API and excipient pharmaceutics Quality attributes Risk analysis Process parameters Design of experiments Design space Normal operating range In-process controls
Product development – key inputs to design stage Variability by different component lots, production operators,
environmental conditions, and measurement systems Use risk analysis tools to screen variables Establish a strategy for process control
51
![Page 52: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/52.jpg)
QUALITY BY DESIGN (QbD) 1. Quality target product profile (QTTP) 2. Critical quality attributes (CQA), critical material
attributes (CMA) 3. Critical process parameters (CPP) 4. Design space 5. Scale-up and technology transfer 6. Identify input variables 7. Input variable control strategy 8. Continuous improvement
Other considerations: PAT, Risk analysis 52
![Page 53: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/53.jpg)
53
STAGE 2, PROCESS QUALIFICATION (VALIDATION PERFORMANCE)
1. Design of a facility and qualification of utilities and equipment 2. Process performance qualification 3. PPQ protocol 4. PPQ protocol execution and report
Confirmation at commercial scale of process design information Qualification of equipment, utilities, facilities Performance qualification Conclusion that process consistently produces quality product. Conformance batches • All support systems, documents, training, personnel, etc. in place • Target / nominal operating parameters within design space • Additional testing • Decision to “release process” for routine commercial
manufacturing
![Page 54: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/54.jpg)
STAGE 2, PROCESS QUALIFICATION Conformance Lots
Procedures Validation plans Protocols Sampling Testing Results Plan to maintain validation
ALL EQUIPMENT, ANALYTICAL, AND SUPPORTING SYSTEMS MUST BE QUALIFIED.
54
![Page 55: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/55.jpg)
PERFORMANCE QUALIFICATION APPROACH Higher level of sampling, testing, and scrutiny of process performance.
Protocol should address: • Operating parameters, processing limits, and raw material inputs • Data to be collected and how evaluated • Test to be performed and acceptance criteria • Sampling plan – sampling points, number of samples, frequency • Statistical methods used • Statistical confidence levels • Provisions to address deviations and non-conformances • Facility, utility, and equipment qualification • Personnel training • Status of analytical method validation • Review and approval by appropriate departments and quality unit
DETAILS FROM FDA PV GUIDANCE 55
![Page 56: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/56.jpg)
PERFORMANCE QUALIFICATION APPROACH “The PPQ lots should be manufacturer under normal conditions by
personnel expected to routinely perform each step of each unit operation in the process. Normal operating conditions should cover the utility systems (air handling and water purification), material, personnel environment, and manufacturing procedures.”
PQ report: • Discuss all aspects of protocol • Summarize and analyze data as specified in protocol • Evaluate unexpected observations and additional data • Summarize and discuss non-conformances • Describe corrective actions or changes • Clear conclusions • Approval by appropriate departments and quality unit
DETAILS FROM FDA PV GUIDANCE
56
![Page 57: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/57.jpg)
HEALTH CANADA -- VALIDATION PROTOCOL Minimum information • Objective, scope of coverage of the validation study • Validation team membership, qualifications, and responsibilities • Type of validation – prospective, concurrent, retrospective, re-validation • Number and selection of batches • List of all equipment used. Normal and worst-case operating parameters • Outcome of IQ and OQ for critical equipment • Requirements for calibration of all measuring devices • Critical process parameters and tolerances • Description of processing steps. Copy of master documents • Sampling points, stages of sampling, methods of sampling, sampling plans • Statistical tools for data analysis • Training requirements for processing operators • Validated test methods • Specification for raw and packaging materials and test methods • Forms and charts for documenting results • Format for presentation of results, documenting conclusions, and approval of study
results
57
![Page 58: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/58.jpg)
58
STAGE 3, CONTINUED PROCESS VERIFICATION (VALIDATION MONITORING AND MAINTENANCE)
Activities to assure process remains in validated state Annual Product Review Trend and assess data Study OOS and OOT (Out of Trend) data Timely monitoring of critical operating and performance
parameters. Monitor product characteristics, materials, facilities,
equipment, and SOP changes Establish process history based on ongoing process
performance Improve process Improve control to detect and reduce variability Change control; evaluate impact of change and test as
necessary
![Page 59: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/59.jpg)
CONTINUED PROCESS VERIFICATION
Monitoring Statistical process control (SPC) Trend analysis Change control Continuous improvement Revalidation Management review
STATISTICIAN RECOMMENDED BY FDA
59
![Page 60: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/60.jpg)
CONTINUED PROCESS VERIFICATION ITEMS TO BE REVIEWED • Product and process data • Relevant process trends • Quality of incoming materials or components • In-process material • Finished products • Defect complaints • OOS findings • Deviations • Yield variations • Batch records • Incoming raw material records • Adverse event reports • Production operator and quality staff feedback
Above should help identify possible product / process improvements DETAILS FROM FDA PV GUIDANCE
60
![Page 61: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/61.jpg)
SUMMARY OF FDA GUIDANCE RECOMMENDATIONS
Stage 1: Product Design • QTPP, development information, identification of CQA, CMA, and CPP • Identification of sources of variation and control plan • Experimental studies • Technology transfer / scale up Stage 2: Process Qualification • Protocol requirements • Statistical sampling and acceptance criteria • Equipment qualification and analytical method validation Stage 3: Continued Process Verification • Post PQ plan • APR, batch data, yields, deviations, OOS, non-conformances, etc. • Incoming material data • Change control • Statistical analysis of data / control charting • Product complaints
61
![Page 62: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/62.jpg)
HEALTH CANADA -- VALIDATION MASTER PLAN
• Company philosophy, intentions and approaches to establish performance adequacy
• Management agreement • Meticulous preparation and planning of steps in process • Structured according to SOP • List of items to be validated and schedule • Documentation
62
![Page 63: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/63.jpg)
HEALTH CANADA VALIDATION GUIDELINES
Additional sections • Installation and Operational Qualification • Requalification • Process Validation
– Prospective – Concurrent – Retrospective
• Process Re-Validation – “Periodic review and trend analysis …at scheduled intervals”
• Change control
63
![Page 64: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/64.jpg)
EMA GUIDELINE ON PROCESS VALDIATION Draft March, 2012
• “…applying enhanced process understanding coupled with risk management tools under an efficient quality system as described by ICH Q8, Q9, and Q10.”
• Definition • Continuous process verification (PAT) • Validation “…not a one-off event.” • “A lifecycle approach should be applied linking product
and process development, validation of the commercial manufacturing process, and maintenance of the process in a state of control during routine commercial production.”
64
![Page 65: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/65.jpg)
EMA GUIDELINE ON PROCESS VALDIATION Draft March, 2012
• Traditional process validation – Annex I details
• Continuous process verification • Hybrid approach
65
![Page 66: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/66.jpg)
EMA GUIDELINE ON PROCESS VALDIATION Draft March, 2012
Definitions • Control Strategy • Continued Process Verification • Continuous Process Verification • Critical Process Parameter (CPP) • Critical Quality Attribute (CQA) • Design Space • High Impact Models • Lifecycle • Pharmaceutical Quality System (PQS) • Process Validation
66
![Page 67: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/67.jpg)
FUNDAMENTAL CONCEPTS
• Scientific and technical basis in development (Stage 1)
• Validation (Stage 2 ) confirms tage 1 development
• Acceptable (passing) results are expected. • Validation is not
– R&D, Final stage of development process – Optimization, Fine-tuning, or Debugging
• Monitor and maintain validated state throughout product lifetime (Stage 3).
67
![Page 68: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/68.jpg)
FUNDAMENTAL CONCEPTS • Critical quality attributes (CQA) • Critical process parameters (CPP) related to CQA • Identify and control variation • Statistical applications
– DOE – Statistical Process Control (SPC)
• Rationale and justification – sampling, testing, etc. • Detailed expectations in guidance
– Protocol and results – Monitoring
• Monitoring and maintenance à Continuous improvements
• Risk – All decisions based on risk analysis 68
![Page 69: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/69.jpg)
APPLICATIONS OF PV GUIDANCE
• Processes: Manufacturing, cleaning, packaging, analytical, others
• Equipment, facilities, utilities, others • Other new applications • Quality Systems and compliance
69
![Page 70: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/70.jpg)
PROCESSES Manufacturing Packaging Cleaning Analytical Other
ALL PROCESSES MUST BE APPROPRIATELY DESIGNED AND DEVELOPED, DEMONSTRATE PERFORMANCE, AND BE MONITORED AND MAINTAINED.
PROCESSES MUST BE CONTINUALLY IMPROVED.
70
![Page 71: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/71.jpg)
QUALIFICATION Equipment Facilities Utilities Control systems Computer systems Others
ALL QUALIFIED EQUIPMENT MUST BE APPROPRIATELY DESIGNED AND DEVELOPED, DEMONSTRATE PERFORMANCE, AND BE MONITORED AND MAINTAINED.
QUALIFIED EQUIPMENT MUST BE CONTINUALLY IMPROVED.
71
![Page 72: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/72.jpg)
EQUIPMENT à PROCESSES
HVAC Systems – Process variable incoming air Water Systems – Process variable incoming water
ALL QUALIFIED EQUIPMENT THAT FUNCTIONS AS PROCESSES MUST BE APPROPRIATELY DESIGNED AND DEVELOPED, DEMONSTRATE PERFORMANCE, AND BE MONITORED AND MAINTAINED.
QUALIFIED EQUIPMENT MUST BE CONTINUALLY IMPROVED.
Reference: “The HVAC Process.” Delli Paoli, Alexander. J Validation Technology, Volume 17, #4, Autumn 2011.
72
![Page 73: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/73.jpg)
QUALITY SYSTEMS FDA QUALITY SYSTEMS • Quality system • Material system • Production and equipment system • Laboratory system
ALL QUALITY SYSTEMS MUST BE APPROPRIATELY DESIGNED AND DEVELOPED, DEMONSTRATE PERFORMANCE, AND BE MONITORED AND MAINTAINED.
QUALITY SYSTEMS MUST BE CONTINUALLY IMPROVED.
73
![Page 74: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/74.jpg)
IMPLEMENTATION • MPLEMENTATION VERY DIFFICULT
– Time – Cost – Change
• Integration of Validation Approval Committee, R&D/technical groups, and QA functions
• Lifecycle involvement – new to traditional validation • Technical groups not accustomed to validation • Post PQ monitoring
– Prescribed testing based on risk – Special testing
• Enhanced PQ and post PQ execution as prescribed in guidance (statistics, etc.)
• Note direction of global guidances, conferences, meetings
• Great challenges for validation personnel 74
![Page 75: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/75.jpg)
SUMMARY PROCESS VALIDATION GUIDANCES
Process Validation Guidances have greatly expanded the scope of validation
• Lifecycle approach – documents from development through commercialization
– Understanding – Demonstration – Monitoring and maintenance
• Traditional validation documents (protocol and results) less important
Validation organizations should lead sites in transition to lifecycle approach
• Multiple groups at site must now contribute to process validation lifecycle approach
75
![Page 76: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/76.jpg)
76
SUMMARY WHERE WE ARE -- CURRENT PRACTICE
R&D Validation Commercialization
![Page 77: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/77.jpg)
77
SUMMARY -- VALIDATION – CURRENT PRACTICE
Emphasis on repeatability (3x) One-time effort Documentation important Last step in development “Hope we can pass validation” Required for product release to market Key regulations:
• 1987 Process Validation Guidance • 1990’s Pharma Inspection Guidelines • 1997 Medical Device Quality Systems Manual
![Page 78: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/78.jpg)
78
SUMMARY -- WHERE WE ARE GOING – LIFECYCLE APPROACH TO PROCESS VALIDATION
Lifecycle approach: • Validation is never completed • Validation is always ongoing
Objectives: • Scientific and technical process • Demonstrate process works as intended • Process must remain in control throughout lifecycle
EFFECTIVE IMPLEMENTATION AND EFFECTIVE DOCUMENTS CONSISTENT WITH THE ABOVE
![Page 79: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/79.jpg)
79
LIFECYCLE APPROACH TO PROCESS VALIDATION
Process Design and Development – Pre-validation work • Studies to establish process • Identify critical process parameters • Identify sources of variation • Consider range of variation possible in processes • Process understanding
Process Qualification • Equipment, facilities, and utilities qualified • Analytical methods validated • Confirm commercial process design • Validation performance
Maintaining the Validated State • Monitor, collect information, assess • Maintenance, continuous verification, process improvement • Change control
• Validation maintenance
“The process of process validation.” All activities based on risk.
![Page 80: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/80.jpg)
80
SUMMARY PROCESS VALIDATION HISTORY
1978 CGMP includes Validation 1987
Development -- VALIDATION -- Control
2004-2011
Lifecycle approach Continuum of understanding – validation – maintenance
UNDERSTANDING -- VALIDATION -- MAINTENANCE
![Page 81: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/81.jpg)
81
SUMMARY VALIDATION -- FUTURE
Development Performance Maintenance
Stage 1 à Stage 2 à Stage 3
![Page 82: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/82.jpg)
SUMMARY – FUNDAMENTAL CONCEPTS
• Lifecycle approach • Scientific and technical basis in development • Validation is confirmation • Monitor and maintain • Management review • Continuous improvements • Risk analysis
82
![Page 83: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/83.jpg)
SUMMARY – FUNDAMENTAL CONCEPTS
• CQA and CPP • Variation – identify and control • Statistical applications
– DOE – Statistical Process Control (SPC)
• Rationale and justification • Risk analysis – work appropriate for level of risk
• Enhanced detailed requirements in guidance – Protocol and results – Monitoring
83
![Page 84: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/84.jpg)
SUMMARY -- APPLICATIONS
Manufacturing process validation Other processes – cleaning, packaging,
analytical, etc. Equipment, facilities, utilities, computer
systems, etc. Equipment processes – HVAC, water
THERE IS NO ARGUMENT AGAINST DESIGN, DEMONSTRATE, AND MAINTAIN
LIFECYCLE APPROACH INCREASING APPLICATIONS
84
![Page 85: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/85.jpg)
SUMMARY FINAL
Lifecycle Approach Status -- 2012: • Lifecycle approach globally accepted
– Health Canada 2004 – FDA 2011 – EMA draft issued March, 2012
• Design à Demonstrate à Maintain: No argument • Approach specifics (QbD, CQA, etc.) accepted and
consistent with ICH and other guidances • Usage increasing – Application to equipment, facilities,
utilities, computers, quality systems, etc. Stage approach and associated concepts increasing application. UNDERSTANDING à PERFORMANCE à MAINTENANCE
85
![Page 86: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/86.jpg)
SUMMARY FINAL -- DID WE MEET OBJECTIVES? • What is the lifecycle approach? • Is the lifecycle approach new? • How is it different? • What are fundamental principles? • US only or global? • Is industry accepting this approach? • Audit questions:
What is your approach to validation? What is your approach to quality systems? UNDERSTAND – DEMONSTRATE -- MAINTAIN
86
![Page 87: Process Validation Guidances FDA and Global](https://reader034.fdocuments.in/reader034/viewer/2022052522/554b85f1b4c90561588b50a9/html5/thumbnails/87.jpg)
PAUL L. PLUTA, PhD
Editor-in-Chief Journal of Validation Technology Journal of GXP Compliance
Advanstar Communications, USA
Visiting Clinical Associate Professor University of Illinois at Chicago (UIC) College of Pharmacy
Chicago, IL, USA
Extensive pharmaceutical industry experience
Contact: [email protected]
87